Pemetrexed Cisplatin First Line
Executive Summary
Pemetrexed (Alimta) combined with cisplatin was approved by the FDA in 2004 for malignant pleural mesothelioma that is unresectable or otherwise not a candidate for curative surgery.[1][2] In the phase III trial that compared the combination with cisplatin alone in chemotherapy-naive patients, median overall survival was 12.1 months versus 9.3 months, and the response rate was 41.3% versus 16.7%.[3] The CheckMate 743 trial, published in 2021, found that first-line nivolumab plus ipilimumab extended overall survival compared with platinum plus pemetrexed chemotherapy, the trial's comparison arm.[4]
At-a-Glance
- FDA approved 2004 for unresectable malignant pleural mesothelioma in combination with cisplatin[1][2]
- Pivotal evidence: EMPHACIS phase III trial (Vogelzang et al., 2003), pemetrexed + cisplatin vs cisplatin alone[5][3]
- Median overall survival: 12.1 months (Pem+Cis) vs 9.3 months (Cis alone)[3]
- Objective response rate: 41.3% (Pem+Cis) vs 16.7% (Cis alone)[3]
- Vitamin supplementation required — daily folic acid (350–1000 µg studied) and vitamin B12 1000 µg every 3 cycles (about 9 weeks)[2]; adding them during the pivotal trial significantly reduced toxicity[3]
- Current standing: CheckMate 743 compared first-line nivolumab + ipilimumab with platinum plus pemetrexed chemotherapy and found longer overall survival with the immunotherapy[4]
- Labeled scope: disease that is unresectable, or patients who are otherwise not candidates for curative surgery[2]
- Median time to progression: 5.7 months (Pem+Cis) vs 3.9 months (Cis alone)[3]
Key Facts
| Fact | Detail |
|---|---|
| FDA approval | February 4, 2004 (NDA 021462), in combination with cisplatin[1] |
| Labeled indication | Malignant pleural mesothelioma that is unresectable, or patients not candidates for curative surgery[2] |
| Regimen | Pemetrexed 500 mg/m² + cisplatin 75 mg/m² IV, day 1 of each 21-day cycle[3] |
| Median overall survival | 12.1 months vs 9.3 months with cisplatin alone (hazard ratio 0.77)[3] |
| Response rate | 41.3% vs 16.7% with cisplatin alone[3] |
| Median time to progression | 5.7 months vs 3.9 months[3] |
| Later comparison | Comparison arm (platinum + pemetrexed) in CheckMate 743, where first-line nivolumab + ipilimumab extended overall survival[4] |
Mechanism and Regimen
Pemetrexed is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, folate-dependent enzymes involved in making thymidine and purine nucleotides.[2] In laboratory studies with the MSTO-211H mesothelioma cell line, pemetrexed given together with cisplatin showed synergistic effects.[2] Standard dosing is pemetrexed 500 mg/m² plus cisplatin 75 mg/m², both administered intravenously on day 1 of a 21-day cycle.[3] The label requires patients to take folic acid and vitamin B12 to reduce treatment-related hematologic and gastrointestinal toxicity. In the pivotal trial's combination arm, grade 3/4 neutropenia occurred in 24% of the 168 fully supplemented patients versus 38% of the 32 never-supplemented patients.[2]
Where This Regimen Fits in 2026
In 2020 the FDA approved nivolumab in combination with ipilimumab for adults with unresectable malignant pleural mesothelioma.[6] In CheckMate 743, which enrolled previously untreated patients, the combination extended overall survival compared with a concurrent platinum plus pemetrexed chemotherapy arm.[4] On September 17, 2024, the FDA approved pembrolizumab with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma, based on the KEYNOTE-483 trial.[7]
References
- ↑ 1.0 1.1 1.2 U.S. Food and Drug Administration. Drugs@FDA: ALIMTA, NDA 021462, approval history (ORIG-1, approved 02/04/2004). Drugs@FDA NDA 021462
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 U.S. Food and Drug Administration. ALIMTA (pemetrexed for injection) prescribing information. NDA 021462, original approval February 4, 2004. Label (PDF)
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. PMID: 12860938.
- ↑ 4.0 4.1 4.2 4.3 Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. PMID: 33485464.
- ↑ Manegold C. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Semin Oncol. 2003;30(4 Suppl 10):32-36. doi:10.1016/s0093-7754(03)00283-5. PMID 12917819. PubMed
- ↑ U.S. Food and Drug Administration. OPDIVO (nivolumab) supplemental BLA 125554/S-089 approval letter: in combination with ipilimumab, for adult patients with unresectable malignant pleural mesothelioma. Signed October 2, 2020. Approval letter (PDF)
- ↑ U.S. Food and Drug Administration. FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. September 17, 2024. FDA